Company intelligence / Profile preview

SWITCHWON

South San Francisco, California, United Statesswitchwon.com ↗

Ownership: Private
Development stage: Commercial

Overview

Switch Therapeutics has launched with $52 million in Series A funding to advance its proprietary CASi platform, which enables cell-selective activation of siRNA therapeutics. The company’s first disclosed program targets APOE for CNS indications and remains at the preclinical stage. No clinical results have been reported as of June 2025.

Therapeutic areas: Neurology
Modalities: Small interfering RNAAntisense oligonucleotideRNA therapy
Industry: Biotech

Partnerships

None publicly disclosed as of June 2025.

Beyond the preview

Go deeper on SWITCHWON.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SWITCHWON.

Explore the full profile